Table 1 Overview of FDA-approved ADC drugs
From: A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
company | generation | ADC drug (brand name) | target | isotype | antibody | linker | payload | average DAR | tumor types | approval date |
|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | First | Gemtuzumab Ozogamicin (Mylotarg) | CD33 | IgG4κ | Gemtuzumab | hydrazone | Calicheamicin | 2–3 | AML | May 17, 2000 Sep 1, 2017 |
Seagen, Takeda | Second | Brentuximab Vedotin (Adcetris) | CD30 | IgG1κ | Brentuximab | mc‒VC‒PABC | MMAE | 4 | HL, ALCL | Aug 19, 2011 |
Genentech | Second | Trastuzumab Emtansine (Kadcyla) | HER2 | IgG1κ | Trastuzumab | SMCC | DM1 | 3.5 | Breast cancer | Feb 22, 2013 |
Pfizer | Second | Inotuzumab Ozogamicin (Besponsa) | CD22 | IgG4κ | Inotuzumab | hydrazone | Calicheamicin | 5–7 | ALL | Jun 28, 2017 (EMA) Aug 17, 2017 (FDA) |
AstraZeneca | Second | Moxetumomab Pasudotox (Lumoxiti) | CD22 | IgG4κ | Moxetumomab | mc‒VC‒PABC | PE38 | 1.8 | HCL | Sep 13, 2018 |
Genentech | Third | Polatuzumab Vedotin (Polivy) | CD79b | IgG1κ | Polatuzumab | mc‒VC‒PABC | MMAE | 3.5 | DLBCL | Jun 10, 2019 |
Astellas, Seagen | Third | Enfortumab Vedotin (Padcev) | Nectin-4 | IgG1κ | Enfortumab | mc‒VC‒PABC | MMAE | 3.8 | UC | Dec 18, 2019 |
AstraZeneca, Daiichi Sankyo | Third | Trastuzumab Deruxtecan (Enhertu) | HER2 | IgG1κ | Trastuzumab | tetrapeptide | DXD | 7–8 | Breast cancer | Dec 20, 2019 |
Gilead Sciences | Third | Sacituzumab Govitecan (Trodelvy) | TROP2 | IgG1κ | Sacituzumab | CL2A | SN-38 | 7.6 | Breast cancer UC | Apr 22, 2020 |
RemeGen | Third | Disitamab Vedotin (Aidixi) | HER2 | IgG1κ | Disitamab | mc‒VC‒PABC | MMAE | 4 | GC UC | Jun 8, 2021 (NMPA) |
ADC Therapeutics | Third | Loncastuximab Tesirine (Zynlonta) | CD19 | IgG1κ | Loncastuximab | mc‒VC‒PABC | PBD SG3199 | 2.3 | DLBCL | Apr 23, 2021 |
Seagen | Third | Tisotumab Vedotin (Tivdak) | TF | IgG1κ | Tisotumab | mc‒VC‒PABC | MMAE | 4 | Cervical cancer | Sep 20, 2021 |
ImmunoGen | Third | Mirvetuximab Soravtansine (Elahere) | FRα | IgG1κ | Mirvetuximab | Sulfo-SPDB | DM4 | 3.3-5 | Ovarian cancer | Nov 14, 2022 |